RSV vaccine safety study in healthy adults
Part of Infections, Lungs & breathing clinical trials.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must be in generally good health.
- Your weight must be at least 110 pounds (women) or 121 pounds (men), and your body mass index (BMI) must be between 18.5 and 35.
- If you are of childbearing age, you must use birth control or not be sexually active during the study.
- You must not have received any RSV vaccine before.
- You must not have a history of heart disease, Guillain-Barré syndrome, or other serious conditions.
- fitModel.tags
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.